Skip to content

Schering-Plough SGP Total Equity

Total Equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
Glaukos logo
GlaukosGKOS
$670.93M-12.2%
AbbVie logo
AbbVieABBV
-$6.66B-569%
Bausch + Lomb logo
Bausch + LombBLCO
$6.38B+0.3%
HRO
HarrowHROW
$28.71M-49.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's total equity?
Schering-Plough (SGP) reported total equity of $250.11M in Q1 2026.
How has Schering-Plough's total equity changed year-over-year?
Schering-Plough's total equity increased by 463.3% year-over-year, from -$68.85M to $250.11M.
What is the long-term trend for Schering-Plough's total equity?
Over 2 years (2023 to 2025), Schering-Plough's total equity has grown at a 73.1% compound annual growth rate (CAGR), from -$32.99M to -$98.84M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.